|
|
|
|
|
|
Sponsored by: |
Thomas Jefferson University |
Information provided by: | Thomas Jefferson University |
ClinicalTrials.gov Identifier: | NCT00408928 |
The purpose of this research study is to test the safety and effectiveness of VELCADE® in the treatment of acute GVHD that has not responded to steroids or has worsened when the steroid dose was decreased. VELCADE® is a drug that inhibits certain immune reactions that happen when lymphocytes encounter foreign substances. We are doing this research to determine if VELCADE® may be useful in treating GVHD.
Condition | Intervention | Phase |
Graft-Versus Host Disease |
Drug: Bortezomib |
Phase II |
Drug Information available for: | Bortezomib |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment |
Official Title: | Phase–II Trial of VELCADE® (Bortezomib) for Steroid Refractory Acute GVHD |
You have graft-versus-host disease (GVHD). You are being asked to take part in this research study because there has been no improvement with steroid treatment. There is no standard treatment for your situation. This research study will test the safety and effectiveness of VELCADE® in the treatment of acute GVHD that has not responded to steroids or has worsened when the steroid dose was decreased.
A maximum number of 27 patients will be enrolled in this study. GVHD is a serious complication after bone marrow transplantation from another donor. GVHD is caused by certain cells called lymphocytes. Normally these cells make immune reactions that help protect the body from foreign substances that cause infection. Here, these cells attack the normal tissues of the body as if they were foreign substances. This interferes with the normal function of vital organs and results in their damage. In GVHD these cells attack the skin, liver and bowel. GVHD also increases the chances of infection.
VELCADE® is a drug that inhibits certain immune reactions that happen when lymphocytes encounter foreign substances. We are doing this research to determine if VELCADE® may be useful in treating GVHD.
VELCADE® is approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma in patients who have received at least two prior therapies and have demonstrated disease progression on their last therapy. Its effectiveness is also being tested in other cancers. The dose of the drug being used in this research study is the same as what is used for the treatment of multiple myeloma. It has not been approved by the FDA for use in GVHD. Therefore, using VELCADE® for GVHD is experimental in this research study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: (All criteria must be met)
Has been treated with a minimum of 2mg/kg of methylprednisolone per day or equivalent dose of steroids and either one of the following:
Exclusion Criteria: (Any one criteria will exclude patient)
Contact: Bijoyesh Mookerjee, MD | 215-955-8289 | Bijoyesh.Mookerjee@mail.tju.edu |
United States, Pennsylvania | |||||
Thomas Jefferson University, Department of Medical Oncology, 111 South 11th St., Gibbon Bldg., Suite 4240 | Recruiting | ||||
Philadelphia, Pennsylvania, United States, 19107 | |||||
Contact: BIJOYESH P MOOKERJEE, MD 215-955-8874 Bijoyesh.Mookerjee@mail.tju.edu | |||||
Principal Investigator: Bijoyesh P Mookerjee, MD |
Thomas Jefferson University |
Principal Investigator: | BIJOYESH P MOOKERJEE | Thoomas Jefferson University, Department of Medical Oncology |
Study ID Numbers: | 04U.177 |
First Received: | December 6, 2006 |
Last Updated: | January 29, 2007 |
ClinicalTrials.gov Identifier: | NCT00408928 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|